Lumipulse G1200

Whether you’re advancing translational research or supporting late-stage biomarker programs, the LUMIPULSE® G1200 offers a fully automated, high-throughput immunoassay platform designed to deliver sensitive, reliable biomarker data.

KCAS Bio's LUMIPULSE® G1200 instrumentation

The LUMIPULSE® G1200 is a robust fully automated immunoassay device, CE marked. Employing an innovative single-test cartridge system, it achieves a throughput of 120 tests per hour, delivering exceptional adaptability and easy handling.

What is the CLEIA technology used by the Lumipulse platform?

At the core of the LUMIPULSE G platform is ChemiLuminescent Enzyme Immuno Assay (CLEIA) technology. CLEIA combines highly specific immunochemical reactions with chemiluminescence, where light is emitted as the result of a chemical reaction. By labeling antibodies with chemiluminescent probes, directly or indirectly, CLEIA enables sensitive and precise detection of a wide range of analytes, including antigens, antibodies, hormones, enzymes, while maintaining excellent analytical performance.

At KCAS Bio, we combine technical expertise and capabilities with state-of-the-art operational infrastructure so that we can scale and adapt quickly to the needs of your project.

'Quality by design' drives every aspect of our work. Our facilities, security and IT infrastructure ensure your samples remain protected at all times, while cultivating excellence and innovation among our scientists.

Explore our labs & locations

Partnership value

Through our collaboration with Fujirebio, we can support our sponsors in different stages of their therapeutic program and according to their specific neuro biomarker needs. We can provide our clients with Fujirebio’s unique NExT concept, offering custom assay development, the novel ADXPLORER® Lumipulse® G assays up to the commercially available RUO and fully qualified IVD Lumipulse G immunoassays.

These ready-to-use kits provide sponsors with faster access to analytically robust immunoassays beyond early prototypes. By bridging the gap between biomarker discovery and clinical application that can take years, these assays support already confident data generation, accelerate biomarker validation, and ultimately help drive translational drug development forward.

Did You Know?

What you didn’t know about the LUMIPULSE G instrument and Lumipulse kits.

The Lumipulse G portfolio presents a broad range of neurological biomarker.

The LUMIPULSE G platform provides an extensive neurological biomarker portfolio, covering both CSF and blood-based markers. The possible clinical domains for application of the biomarkers within the NExT (Neuro Expert Toolbox) portfolio range from Alzheimer’s disease, Parkinson’s disease, motor neuron diseases such as amyotrophic lateral sclerosis, multiple sclerosis, as well as psychiatric conditions covering various pathophysiological mechanisms.

Lumipulse® G kits and instrument deliver highly reliable results.

Lumipulse G kits include single-use cartridges with all assay-specific reagents included. In combination with the fully automated LUMIPULSE G1200 instrument, this set-up reduces operator variability and ensures consistent results across runs, users, and sites. Multi-level controls monitor performance of each run and detect potential instrument drift. For commercial kits, calibration stability is typically proven for one month, while calibration for ADxPLORER® assays is performed weekly. For major neurological markers, the repeatability CVs ranged between 2.0 and 5.6% and the reproducibility CVs ranged between 2.1 and 6.5% % across multicenter evaluations.

LUMIPULSE® G competes with ultrasensitive LBA platforms.

LUMIPULSE G reaches low limits of quantification (LLOQs) for plasma and CSF Aβ42, p-tau181/217, and NfL, aligning with high-sensitive technologies often used in research, such as Simoa® digital immunoassays.

With the LUMIPULSE® G instrument, you can test samples individually

With the LUMIPULSE G instrument, you can test samples individually while maintaining high throughput.There is no need to run a full 96-well plate when only a few samples require retesting. Because the Lumipulse G technology is not plate-based, laboratories are not constrained by batch size per run. This is particularly advantageous for retesting or interim analyses, as only the required samples can be analyzed, reducing reagent waste and turn-around time. Each result is delivered in approximately 35 minutes.

Lumipulse® G supports clinical tests beyond diagnostic applications.

Beyond initial screening, the Lumipulse G portfolio supports monitoring longitudinal biomarker changes related to neuroinflammation (GFAP, sTREM2), neuronal damage (NfL), and neurodegenerative pathways (tau, amyloid-beta). These biomarkers are valuable for assessing safety, treatment response, and disease progression during drug development and clinical trials in neurological disorders such as Alzheimer’s disease.